Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interchangeability of Quintovac and GOBIK 5‑component pediatric vaccines
jRCTs071240005Completed
- Sponsor
- KM Biologics
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised trial of Quintovac and vilobelimab in Haemophilus influenzae type b disease (Hib), pertussis, diphtheria and 2 more (4 arms), sponsored by KM Biologics. Primary endpoint: Seropositivity rate against polyribosyl ribitol phosphate (≥ 1 µg/mL). Started May 2024; status: completed.
02
Drugs
Quintovacvilobelimab
03
Conditions
Haemophilus influenzae type b disease (Hib)pertussisdiphtheriaTetanuspoliomyelitis
Beyond the preview
Go deeper on jRCTs071240005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071240005.